Indian Journal of Sleep Medicine

Register      Login

VOLUME 19 , ISSUE 2 ( April-June, 2024 ) > List of Articles


Sleep-disordered Breathing in an Adult with Mucopolysaccharidosis Type I (Hurler–Scheie Syndrome): A Case Report

Ajay Godse, Sunil Jaisingh, Prachi Shah, Shivanjali Gore

Keywords : Case report, Mucopolysaccharidosis, Obstructive sleep apnea, Polysomnography, Sleep-disordered breathing

Citation Information : Godse A, Jaisingh S, Shah P, Gore S. Sleep-disordered Breathing in an Adult with Mucopolysaccharidosis Type I (Hurler–Scheie Syndrome): A Case Report. Indian Sleep Med 2024; 19 (2):31-33.

DOI: 10.5005/jp-journals-10069-0132

License: CC BY-NC 4.0

Published Online: 19-06-2024

Copyright Statement:  Copyright © 2024; The Author(s).


Aim and background: Hurler–Scheie syndrome, also known as mucopolysaccharidosis (MPS) type I, is one of the lysosomal storage diseases, resulting in the accumulation of glycosaminoglycans in various organs. The patient presents with coarse facial features, musculoskeletal deformities, and umbilical hernia with no signs of intellectual disability or corneal involvement in childhood. This case report aims to create awareness among the clinicians to identify, diagnose, and treat the sleep-disordered breathing (SDB) in adult patients of MPS. Case description: This case report highlights the incidence of a 33-year-old adult, who was diagnosed with MPS type I in childhood, and later presented with SDB in his adulthood. The patient was diagnosed with obstructive sleep apnea (OSA) with polysomnography. He was treated with bilevel PAP support in which post-treatment his apnea–hypopnea index (AHI) showed drastic improvement from AHI of 99.2 to AHI of 2. Conclusion: The SDB and OSA are few of the respiratory complications seen in MPS type I. With the advent of new therapies, these pediatric disorders have better survival rates than the past few years. Adult survivors of MPS, thus pose as a novel challenge to physicians in their management. Clinical significance: This case report highlights a new challenge that physicians face with the treatment of adults’ survivors of MPS, who present with SDB.

PDF Share
  1. Kobayashi H. Recent trends in mucopolysaccharidosis research. J Human Genet 2018;64(2):127–137. DOI: 10.1038/s10038-018-0534-8.
  2. Celik B, Tomatsu SC, Tomatsu S, et al. Epidemiology of mucopolysaccharidoses update. Diagnostics 2021;11(2):273. DOI: 10.3390/diagnostics11020273.
  3. Clarke LA. Mucopolysaccharidosis type I. 2016. Available from:
  4. Stepien KM, Bentley A, Chen C, et al. Non-cardiac manifestations in adult patients with mucopolysaccharidosis. Front Cardiovas Med 2022;9:839391. DOI: 10.3389/fcvm.2022.839391.
  5. Lin H-Y, Lee C-L, Chang C-Y, et al. Survival and diagnostic age of 175 Taiwanese patients with mucopolysaccharidoses (1985–2019). Orphanet J Rare Dis 2020;15(1):314. DOI: 10.1186/s13023-020-01598-z.
  6. Khan SA, Peracha H, Ballhausen D, et al. Epidemiology of mucopolysaccharidoses. Mol Genet Metab 2017;121(3):227–240. DOI: 10.1016/j.ymgme.2017.05.016.
  7. Sheth J, Mistri M, Sheth F, et al. Burden of lysosomal storage disorders in India: Experience of 387 affected children from a single diagnostic facility. JIMD Rep 2014;12:51–63. DOI: 10.1007/8904_2013_244.
  8. Muenzer J, Jones SA, Tylki-Szymańska A, et al. Ten years of the Hunter Outcome Survey (HOS): Insights, achievements, and lessons learned from a global patient registry. Orphanet J Rare Dis 2017;12(1):82. DOI: 10.1186/s13023-017-0635-z.
  9. Mitchell J, Berger KI, Borgo A, et al. Unique medical issues in adult patients with mucopolysaccharidoses. Eur J Intern Med 2016;34:2–10. DOI: 10.1016/j.ejim.2016.05.017.
  10. Pal AR, Brown N, Jones SA, et al. Obstructive sleep apnea in MPS: A systematic review of pretreatment and posttreatment prevalence and severity. Journal of Inborn Errors of Metabolism and Screening 2015;3. DOI: 10.1177/2326409815616392.
  11. Kampmann C, Wiethoff CM, Huth RG, et al. Management of life-threatening tracheal stenosis and tracheomalacia in patients with mucopolysaccharidoses. JIMD Rep [Internet] 2017;33:33–39. Available from:
  12. Berger KI, Fagondes SC, Giugliani R, et al. Respiratory and sleep disorders in mucopolysaccharidosis. J Inher Metab Dis 2012;36(2): 201–210. DOI: 10.1007/s10545-012-9555-1.
  13. Battan G, Kumar S, Panwar A, et al. Effect of CPAP therapy in improving daytime sleepiness in Indian patients with moderate and severe OSA. J Clin Diag Res 2016;10(11):OC14–OC16. DOI: 10.7860/JCDR/2016/23800.8876.
  14. Wyatt K, Henley W, Anderson L, et al. The effectiveness and cost-effectiveness of enzyme and substrate replacement therapies: A longitudinal cohort study of people with lysosomal storage disorders. Health Technology Assessment (Winchester, England) 2012;16(39):1–543. Available from:
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.